Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7952745 | 0.97 | HTR5A (0.33) | HTR5AABCC8KCNJ11CXCR1CXCR2 | |
| SCHEMBL7944141 | 0.95 | IL1B (0.33) | ABCC8KCNJ11CXCR1CXCR2 | |
| SCHEMBL6553120 | 0.81 | ABCC8 (0.48) | HTR5AABCC8KCNJ11CXCR2ALDH1A1 | |
| SCHEMBL6553558 | 0.79 | ABCC8 (0.37) | HTR5AABCC8KCNJ11CXCR1CXCR2 | |
| SCHEMBL7944129 | 0.79 | CRHR1 (0.32) | CXCR1CXCR2 | |
| SCHEMBL24050255 | 0.78 | ABCC8 (0.45) | HTR5AABCC8KCNJ11CXCR2ALDH1A1 | |
| SCHEMBL7954367 | 0.77 | CXCR2 (0.32) | ABCC8KCNJ11CXCR1CXCR2ALDH1A1 | |
| SCHEMBL6555285 | 0.77 | ABCC8 (0.53) | HTR5AABCC8KCNJ11CXCR2ALDH1A1 | |
| SCHEMBL7067978 | 0.75 | ABCC8 (0.46) | HTR5AABCC8KCNJ11 | |
| SCHEMBL4260980 | 0.75 | ABCC8 (0.34) | HTR5AABCC8KCNJ11CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-05 | — | — | US | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | HTR5A 1856/4885ABCC8 62/4885KCNJ11 3/4885 |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNK4, KCNK2 | HTR5A 1902/4885ABCC8 67/4885KCNJ11 4/4885 |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | HTR5A 1856/4885ABCC8 62/4885KCNJ11 3/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | HTR5A 1856/4885ABCC8 62/4885KCNJ11 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.